Company recognized for its pioneering multi-omic platform that analyzes over 250 biomarkers from a single blood draw, delivering powerful insights for preventive and precision medicine Vancouver, B.C. – Molecular You,… Read More
Getinge’s Advanta™ V12 is now approved for major bridging indications, marking a milestone in complex aortic aneurysm treatment. Getinge announces that its Advanta™ V12 Covered Stent System has received CE… Read More
Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL) BeOne to participate in Project Orbis program, supporting… Read More
Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable and… Read More
VANCOUVER, B.C. — ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) a publicly listed biotechnology company discovering and developing novel cancer fighting drugs in the field of immuno-oncology, announced… Read More
